GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Jefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

As head of HHS, Kennedy would lead a sprawling federal department that encompasses more than 100 programs supporting medicine ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...

For the remainder of the year, management expects a fall in Vaccine sales due to lower sales of Arexvy and Shingrix. GSK now expects sales to decline by a low-single digit percentage at CER ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

On Tuesday, Jefferies revised its stance on GlaxoSmithKline (NYSE ... potential headwinds for Arexvy & Shingrix, as well as the US Medicare Part D redesign, are likely to temper growth. Despite a ...